Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure
- PMID: 17588300
- DOI: 10.1185/030079907x210723
Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure
Abstract
Therapeutic interventions that block the renin-angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an angiotensin-converting enzyme inhibitor (ACEi) for RAAS blockade. The ARB candesartan was initially established as an effective once-daily antihypertensive treatment, providing 24-h blood pressure (BP) control with a trough:peak ratio close to 100%.
Scope: A Medline literature search was undertaken to identify randomised, controlled trials that examined the efficacy and cardiovascular outcomes associated with candesartan cilexetil in hypertension and chronic heart failure (CHF).
Findings: Compared with other ARBs, candesartan demonstrates the strongest binding affinity to the angiotensin II type 1 receptor. Clinical trials have demonstrated that candesartan is well tolerated in combination with diuretics or calcium channel blockers (CCBs), making it a suitable treatment option for patients whose hypertension is not adequately controlled by monotherapy. Subsequently, candesartan became the only ARB licensed in the UK to treat patients with CHF and left ventricular ejection fraction < or = 40% as add-on therapy to an ACEi or when an ACEi is not tolerated. Studies in patients with symptomatic HF have indicated that candesartan treatment was associated with significant relative risk reductions in cardiovascular mortality and hospitalisation due to CHF.
Conclusions: There are clear indications that the clinical benefits of candesartan may extend beyond its proven antihypertensive effects to a wider range of complications across the cardiovascular continuum, including diabetes, left ventricular hypertrophy, atherosclerosis and stroke. Such results suggest that candesartan treatment may offer significant patient benefits as well as practical advantages over conventional treatment.
Similar articles
-
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.Pharmacoeconomics. 2006;24(12):1249-72. doi: 10.2165/00019053-200624120-00008. Pharmacoeconomics. 2006. PMID: 17129078 Review.
-
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.Vasc Health Risk Manag. 2011;7:749-59. doi: 10.2147/VHRM.S22591. Epub 2011 Dec 12. Vasc Health Risk Manag. 2011. PMID: 22241949 Free PMC article. Review.
-
Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.Expert Opin Pharmacother. 2012 Dec;13(18):2699-709. doi: 10.1517/14656566.2012.745511. Epub 2012 Nov 21. Expert Opin Pharmacother. 2012. PMID: 23170938 Review.
-
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.Vasc Health Risk Manag. 2009;5:1043-58. doi: 10.2147/vhrm.s5549. Epub 2009 Dec 29. Vasc Health Risk Manag. 2009. PMID: 20057897 Free PMC article. Review.
-
Candesartan cilexetil: an update of its use in essential hypertension.Drugs. 2002;62(8):1253-87. doi: 10.2165/00003495-200262080-00016. Drugs. 2002. PMID: 12010090 Review.
Cited by
-
Telmisartan and candesartan promote browning of white adipose tissue and reverse fatty liver changes in high fat diet fed male albino rats.Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):2359-2378. doi: 10.1007/s00210-023-02771-4. Epub 2023 Oct 13. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37831115
-
Evaluation of the Possible Mechanisms of Antihypertensive Activity of Loranthus micranthus: An African Mistletoe.Biochem Res Int. 2011;2011:159439. doi: 10.1155/2011/159439. Epub 2011 Sep 12. Biochem Res Int. 2011. PMID: 21918720 Free PMC article.
-
Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.Drug Des Devel Ther. 2020 May 14;14:1851-1865. doi: 10.2147/DDDT.S248511. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32523332 Free PMC article.
-
Candesartan cilexetil in the treatment of chronic heart failure.Vasc Health Risk Manag. 2009;5(1):257-64. doi: 10.2147/vhrm.s4650. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436650 Free PMC article. Review.
-
Loranthus micranthus Linn.: Biological Activities and Phytochemistry.Evid Based Complement Alternat Med. 2013;2013:273712. doi: 10.1155/2013/273712. Epub 2013 Sep 10. Evid Based Complement Alternat Med. 2013. PMID: 24109490 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous